Who owns ACRIVON THERAPEUTICS INC?
- Ticker: ACRV
- CUSIP Number: 004890109
Tip: Access positions for across all investors
Analyze quarterly positions in Acrivon Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acrivon Therapeutics stock
Who bought or sold ACRIVON THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 8.3M | $15M | 0% | Sep 2025 |
|
| Sands Capital Ventures | 2.1M | $5.1M | 0% | Dec 2025 |
|
| Citadel Advisors | 1.5M | $2.8M | -19% | Sep 2025 |
|
| Wellington Management Company | 888k | $1.6M | 0% | Sep 2025 |
|
| Vanguard Group | 699k | $1.7M | 12% | Dec 2025 |
|
| Renaissance Technologies | 634k | $1.5M | 2% | Dec 2025 |
|
| Acadian Asset Management | 581k | $1.4M | 532% | Dec 2025 |
|
| Marshall Wace | 496k | $1.2M | 231% | Dec 2025 |
|
| Acorn Capital Advisors | 405k | $734k | 0% | Sep 2025 |
|
| UBS Group | 349k | $840k | -49% | Dec 2025 |
|
| Jane Street | 342k | $824k | 18% | Dec 2025 |
|
| BlackRock | 331k | $599k | -19% | Sep 2025 |
|
| Two Sigma Investments | 319k | $578k | 76% | Sep 2025 |
|
| Geode Capital Management | 198k | $478k | 3% | Dec 2025 |
|
| Millennium Management | 185k | $335k | -37% | Sep 2025 |
|
| Two Sigma Advisers | 137k | $247k | 319% | Sep 2025 |
|
| Goldman Sachs Group | 119k | $288k | 505% | Dec 2025 |
|
| State Street Corporation | 67k | $162k | 0% | Dec 2025 |
|
| Northern Trust | 64k | $154k | 51% | Dec 2025 |
|
| Algert Coldiron Investors | 45k | $81k | 100% | Sep 2025 |
|
| Squarepoint Ops | 26k | $63k | -75% | Dec 2025 |
|
| Barclays | 24k | $59k | 22% | Dec 2025 |
|
| Bridgeway Capital Management | 23k | $41k | 0% | Sep 2025 |
|
| Baker Bros. Advisors | 23k | $41k | 0% | Sep 2025 |
|
| Quadrature Capital | 21k | $50k | 100% | Dec 2025 |
|
| XTX Topco | 21k | $50k | -43% | Dec 2025 |
|
| Dimensional Fund Advisors | 18k | $44k | -6% | Dec 2025 |
|
| Schonfeld Strategic Advisors | 16k | $40k | 100% | Dec 2025 |
|
| Susquehanna International | 12k | $30k | 100% | Dec 2025 |
|
| Point72 Asset Management | 11k | $26k | 100% | Dec 2025 |
|
| AAFCPAs Wealth Management | 11k | $26k | 0% | Dec 2025 |
|
| FMR | 8.6k | $16k | -12% | Sep 2025 |
|
| Federated Investors | 5.6k | $14k | 131% | Dec 2025 |
|
| Jpmorgan Chase & Co | 1.7k | $3.2k | 100% | Sep 2025 |
|
| Royal Bank of Canada | 948.00 | $0 | 2958% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 634.00 | $1.5k | -47% | Dec 2025 |
|
| NISA Investment Advisors | 584.00 | $1.4k | 0% | Dec 2025 |
|
| Redwood Park Advisors | 500.00 | $1.2k | 0% | Dec 2025 |
|
| Russell Investments | 481.00 | $1.2k | 0% | Dec 2025 |
|
| Federation des caisses Desjardins du Quebec | 400.00 | $724.000000 | 0% | Sep 2025 |
|
| EverSource Wealth Advisors | 373.00 | $899.004600 | 0% | Dec 2025 |
|
| Optima Capital | 278.00 | $670.007800 | 100% | Dec 2025 |
|
| SBI Securities | 74.00 | $133.999200 | 0% | Sep 2025 |
|
Who sold out of Acrivon Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| AQR Capital Management | Jun 2025 | 22k | $27k |
| Colony | Sep 2025 | 20k | $988k |
| Tower Research Capital | Sep 2025 | 8.7k | $16k |
| China Universal Asset Management | Sep 2025 | 5.5k | $10k |
| Mirae Asset Global Investments | Sep 2025 | 1.2k | $2.2k |
| Gf Fund Management | Sep 2025 | 650.00 | $1.2k |
| CWM | Sep 2025 | 127.00 | $0 |